Trial Profile

A phase I/II of Legutaxel in patients with solid tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs QHL 236 (Primary)
Indications Solid tumours
Focus Adverse reactions
Sponsors Shanghai Affinity Biopharmaceutical

Most Recent Events

23 Dec 2023 assumed the status as recruiting for now, MR says, Legutaxel is about to complete phase I/II clinical trial, pls update further
22 Dec 2023 New trial record
07 Jul 2023 According to Shanghai Affinity Biopharmaceutical media release, company is conducting phase I/II clinical trial for the treatment of solid tumours.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com